World · Singapore Bureau
NUS team identifies drug targeting aggressive breast cancer control mechanism
Researchers at the National University of Singapore have discovered a pharmaceutical compound that can disable a critical regulatory pathway in aggressive breast cancer cells. The breakthrough could pave the way for more targeted and personalised treatment approaches for patients with this challenging malignancy.
LSN Singapore ·
Scientists at NUS have identified a drug candidate capable of suppressing a key molecular 'master switch' that drives the progression of aggressive breast cancer, according to findings from the university's research team. The discovery centres on a regulatory mechanism that, when activated, promotes the growth and spread of cancer cells in particularly treatment-resistant forms of the disease.
The research represents a significant step toward developing more precise therapeutic strategies tailored to individual patients' tumour profiles. By targeting this specific molecular pathway, the drug candidate demonstrates potential to disrupt the processes that enable aggressive breast cancer cells to proliferate and evade conventional treatments.
The findings emerge from detailed molecular and cellular studies conducted at NUS, where researchers systematically analysed the mechanisms underlying aggressive breast cancer subtypes. The identification of this control mechanism provides a concrete target for drug development and offers insights into personalised medicine approaches that could improve treatment outcomes.
Researchers say the discovery could lead to clinical applications within the coming years, pending further preclinical validation and regulatory approval processes. The work underscores Singapore's growing contributions to oncology research and reinforces the potential for regional institutions to develop solutions addressing major health challenges in Asia and beyond.